Printer Friendly

RIBI IMMUNOCHEM EXPANDS COMMERCIAL RELATIONSHIP WITH SMITHKLINE BEECHAM BY PROVIDING ADJUVANTS FOR IMPORTANT GROUP OF BACTERIAL VACCINES

 HAMILTON, Mont., Dec. 17 /PRNewswire/ -- Ribi ImmunoChem Research, Inc. (NASDAQ: RIBI) announced today it has signed an agreement to supply its adjuvants to SmithKline Beecham (NYSE: SBE) for the development of an important group of human bacterial disease vaccines, including some pediatric vaccines.
 Under the agreement, Ribi ImmunoChem granted SmithKline Beecham (SB) a worldwide license to use Ribi's adjuvants commercially upon regulatory approval of the vaccines. SB is actively developing a new generation of combination pediatric vaccines containing diphtheria, pertussis, tetanus, Haemophilus influenzae B (meningitis), hepatitis B and polio antigens and is in early research with several other bacterial vaccines. In addition to an annual license fee, Ribi will receive transfer payments for supplies of the adjuvants and will be entitled to royalties from SmithKline Beecham upon commercial sale of the vaccines.
 "We are very excited about our contribution toward improving human health care through this important group of vaccines, especially the new pediatric vaccines," said Robert E. Ivy, chief executive officer, president and chairman of Ribi ImmunoChem. "The annual potential patient population for some of these vaccines has been conservatively estimated at 7.6 million children. With commercialization Ribi will realize revenues from transfer payments and royalties."
 This is the second license agreement Ribi has entered into with SB providing for the use of Ribi adjuvants in SB vaccines. The first license agreement for a number of adult vaccines also provides for transfer payments to Ribi for supplies of adjuvant and royalties upon commercialization and was announced in May 1991. SB is actively researching vaccines against Lyme disease, herpes, hepatitis A, B and E and malaria and has initiated human clinical testing of certain of these vaccines.
 "We are equally excited about the potential of the vaccines covered by the 1991 agreement to improve health care for children and adults at risk," said Mr. Ivy. "The potential for products embodied by these agreements could generate significant revenues for Ribi."
 Ribi also entered into a one-year research and collaboration agreement with SB pursuant to which Ribi will perform certain research for SB related to certain adjuvants and vaccines. The agreement, which is renewable, is funded by SB.
 In addition to the adjuvant license agreements with SmithKline Beecham, Ribi is also supplying DETOX(TM)-B adjuvant for use in the clinical development of THERATOPE(R) therapeutic adenocarcinoma vaccine by Biomira Inc. of Edmonton, Alberta, for therapy of breast, lung, colorectal and ovarian cancers. Other Ribi ImmunoChem products include MELACINE(R) melanoma theraccine (therapeutic vaccine), which is in two pivotal controlled Phase III human clinical studies, and MPL(R) immunostimulant, which is being developed to prevent or ameliorate sepsis and septic shock as well as cardiac reperfusion injury.
 SmithKline Beecham is one of the world's leading health care companies, with principal activities including the discovery, manufacture and marketing of both human and veterinary pharmaceuticals, over-the-counter medicines and health-related consumer brands as well as clinical laboratory testing.
 Ribi ImmunoChem Research, Inc., a biopharmaceutical company founded in 1981, is a leader in the development of immunostimulants for use in preventing and treating human and animal diseases.
 -0- 12/17/92
 /CONTACT: Jeffrey S. McDowell, corporate information manager of Ribi ImmunoChem, 406-363-6214, ext. 153/
 (RIBI SBE)


CO: Ribi ImmunoChem Research, Inc.; SmithKline Beecham ST: Montana IN: MTC SU:

PS -- NY012 -- 8071 12/17/92 09:22 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 17, 1992
Words:552
Previous Article:/C O R R E C T I O N -- ITAR-TASS/
Next Article:UNION CARBIDE TO REDEEM 15 PERCENT DEBENTURES DUE 2006
Topics:


Related Articles
MICHIGAN DEPARTMENT OF PUBLIC HEALTH AND SMITHKLINE BEECHAM ANNOUNCE VACCINE COLLABORATION
PASTEUR MERIEUX SERUMS ET VACCINS AND SMITHKLINE BEECHAM ANNOUNCE VACCINE AGREEMENT
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
SMITHKLINE BEECHAM ANNOUNCES PEDIATRIC VACCINE AGREEMENT WITH MEDEVA
SMITHKLINE BEECHAM TO INTRODUCE HAVRIX, HEPATITIS A VACCINE, IN THE PEOPLE'S REPUBLIC OF CHINA
SMITHKLINE BEECHAM AND CLINTRIALS RESEARCH INC. ANNOUNCE AGREEMENT FOR CLINICAL TRIALS
SMITHKLINE BEECHAM AND VIRUS RESEARCH INSTITUTE ANNOUNCE COLLABORATION FOR MICROBIAL RESEARCH
TULANE UNIVERSITY AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
Ribi ImmunoChem's MPL Adjuvant System Critical to Efficacy of Malaria Vaccine in Human Challenge Study
Schering-Plough Acquires Marketing Rights to Ribi's Melacine in Canada

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters